Investigating whether patient-specific machine learning can anticipate hypoglycaemic events early enough to support proactive, life-saving intervention.
Madhu-AI is a machine-learning platform being developed for robust, patient-specific hypoglycaemia prediction. It combines continuous glucose monitoring telemetry, multi-cohort clinical pre-training, and leakage-free causal calibration to investigate early-warning prediction of hypoglycaemic events and support more proactive diabetes care.
Hypoglycaemia is not merely an inconvenient blood sugar dip—it is an acute, life-threatening clinical emergency that inflicts severe physical, neurological, and emotional trauma on millions of insulin-dependent patients every single day.
The human brain depends almost entirely on continuous glucose perfusion to maintain consciousness and autonomic regulation. When blood glucose drops precipitously, brain cellular starvation rapidly triggers neuroglycopenia, leading to seizures, profound coma, irreversible cognitive injury, cardiac arrhythmias, and sudden unexpected death in bed.
More than 50% of severe hypoglycaemic episodes occur overnight while patients are asleep. Natural autonomic counter-regulatory wake-up mechanisms are severely blunted during deep sleep. Parents of diabetic children and spouses live in constant dread of nocturnal emergencies, causing chronic insomnia and debilitating psychological fear.
Repeated episodes trigger Hypoglycaemia-Associated Autonomic Failure (HAAF), progressively extinguishing the early adrenaline warning signals (sweating, palpitations, trembling). Patients enter severe neurological confusion while operating machinery, driving, or working—unaware they are in mortal danger until motor collapse occurs.
Acute hypoglycaemia triggers hundreds of thousands of emergency ambulance callouts and intensive care admissions annually. Terrified of experiencing low blood sugars, many patients intentionally maintain dangerously elevated glucose levels—sacrificing their long-term vascular health and accelerating diabetic retinopathy, kidney failure, and limb amputations.
Understanding why anticipating glucose crashes requires moving far beyond simplistic reactive threshold buzzers and linear trend heuristics.
Interstitial glucose levels do not descend in uniform straight lines. Meals, variable digestive rates, exertion, circulating insulin, and circadian hormonal rhythms create irregular, non-linear velocity shifts that defy basic linear extrapolations.
Two individuals with identical baseline readings often respond very differently to the same metabolic demands. Insulin sensitivity, counter-regulatory hormonal reserves, and hypoglycaemia unawareness vary widely across patients, necessitating patient-specific adaptation.
Conventional CGM alerts primarily fire after blood glucose has already crossed an acute threshold (e.g., 70 mg/dL), or provide less than 15–20 minutes of warning—often too late for ingested carbohydrates to absorb before neuroglycopenic symptoms emerge.
Attempting to extend warning horizons with crude trend rules frequently inundates patients with high false-positive rates. Patients suffering from alert fatigue may disable warnings entirely, defeating the clinical safety objective.
From continuous interstitial sensor telemetry to calibrated, actionable early-warning alerts running natively on the user's phone.
Standardises heterogeneous 5-minute and 15-minute sensor streams through an on-device adapter layer, preserving timestamps and signal continuity.
Extracts velocity, acceleration vectors, and past temporal sequences while enforcing strict causal past-only boundaries.
Initialises representations across multi-cohort clinical populations to capture generalisable human glycaemic dynamics.
Calibrates prediction parameters on the user's smartphone to the individual's unique historical variance and personalized metabolic profile.
Generates early-warning risk estimates with extended lead-times, balancing proactive utility against false-alert burden.
Madhu-AI models are designed with extreme computational efficiency in mind. By keeping memory footprints minimal and eliminating complex matrix operations during inference, the pipeline operates locally on commercial smartphones paired over Bluetooth with CGM sensors, maintaining real-time vigilance without battery drain or cloud dependencies.
Three foundational research principles engineered to eliminate data leakage and support realistic forecasting conditions.
Generalised population models frequently fail to account for personal circadian rhythms, insulin clearance rates, and individual physical activity responses. Madhu-AI investigates how models can be tailored to individual patients' temporal profiles, providing personalized risk boundaries rather than one-size-fits-all population estimates.
Single-cohort models often overfit to specific sensor brands or local hospital demographics. By evaluating representations learned across multiple distinct clinical cohorts, Madhu-AI investigates generalisable representations that serve as a robust baseline before patient-specific fine-tuning.
In published time-series literature, a frequent flaw is retrospective data leakage—such as bidirectional filtering, future-window normalization, or random train/test splits. Madhu-AI strictly enforces past-only causal temporal partitions, ensuring the evaluation reflects realistic clinical forecasting conditions.
All feature transformations, imputation, scaling, and calibration are computed using past observations only. No data beyond the cutoff boundary t₀ can influence model representations.
Empirical evaluation results documented across four independent external validation cohorts encompassing both Type 1 and Type 2 diabetes populations under strict past-only causal testing.
Demonstrating consistent discriminatory precision across multiple independent external validation cohorts under past-only causal partitions.
Consistently capturing impending hypoglycaemic events across heterogeneous sensor protocols (5-minute and 15-minute sampling rates).
Provides substantial early warning buffer before acute hypoglycaemic threshold crossing occurs across all evaluated cohorts.
Maintained within an acceptable clinical burden of approximately 1 to 2 false alerts per patient-day across all tested cohorts.
Evaluated across multiple independent external clinical validation cohorts following pre-training development.
Clinically meaningful declines below 80 mg/dL, with a forecast horizon calibrated to anticipate hypoglycaemic events before acute symptoms manifest.
The duration from the initial triggered early-warning alert to the true onset of the hypoglycaemic episode.
A conceptual comparison of prevailing glucose monitoring methods and the potential differentiation explored by the Madhu-AI research framework.
| Dimension | Fixed Threshold Alarms | Simple Linear Extrapolations | Non-Adaptive Population Models | Madhu-AI Framework |
|---|---|---|---|---|
| Primary Function | Post-threshold boundary alert | Short-range trajectory extrapolation | Generalised population risk scoring | Patient-specific anticipatory forecasting |
| Warning Lead-Time | Minimal (< 15 minutes) | Short (15–30 minutes) | Moderate (30–45 minutes) | Extended (> 50–80 minutes mean) |
| Patient Personalisation | None (Standard static cutoff) | None (Uniform slope formulas) | Limited (Generic demographic filters) | Patient-aware temporal calibration |
| Deployment Footprint | Basic firmware threshold | Basic firmware slope check | Heavy cloud processing required | Ultra-lightweight on-device smartphone execution |
| Causal Boundary Validation | N/A (Hardware instantaneous) | Real-time buffer only | Frequently compromised by retrospective smoothing | Strict past-only temporal partitioning |
| Alert Burden Balance | High latency, low predictive utility | Elevated noise-triggered false alerts | Variable across patient sub-populations | Calibrated false-alert burden (~1–2/day) |
*Note: Comparisons reflect conceptual paradigms. Superiority under real-world clinical deployment remains subject to ongoing prospective research and formal regulatory evaluation.
Evaluated across distinct international clinical populations to assess model stability across varying physiological backgrounds and sensor sampling frequencies.
The research pipeline is engineered to support both high-frequency 5-minute sampling rates and 15-minute continuous glucose monitoring intervals, integrating interstitial glucose dynamics, calculated velocity, and temporal contextual signals.
The framework has been evaluated across distinct international research cohorts encompassing adult Type 1 and Type 2 diabetes cohorts to assess model stability across varying physiological and demographic environments.
All training and external validation research utilizes fully anonymized, ethically de-identified clinical telemetry. No patient-identifying information or proprietary source repositories are exposed within model interfaces.
Addressing the acute vulnerabilities of insulin-dependent life where standard reactive CGM monitors currently fail patients.
During deep REM sleep, autonomic arousal is suppressed. Madhu-AI provides an anticipatory 50-to-80-minute lead time, triggering escalating auditory alarms while the patient is still cognitively competent to self-treat, or activating smart-home and caregiver alerts before loss of consciousness occurs.
For patients who cannot feel low blood sugars due to autonomic neuropathy or repeated hypoglycemia, Madhu-AI acts as a synthetic autonomic warning system. Operating directly on their phone, it alerts them prior to driving, strenuous work, or lone travel.
In step-down units and general hospital wards, intensive insulin titration carries massive risk of unobserved iatrogenic hypoglycaemia. Anticipatory forecasting allows nursing teams to preemptively adjust intravenous dextrose or oral intake before cardiac destabilisation occurs.
Existing predictive low glucose suspend (PLGS) insulin pumps only halt basal delivery 20 to 30 minutes in advance—often after subcutaneous insulin depots have already sealed a patient's fate. An extended forecast horizon allows automated pumps to suspend basal delivery early enough to genuinely blunt the crash.
Madhu-AI focuses on the critical gap between reactive alarm systems and actionable anticipatory forecasting.
Detecting that a patient's glucose is currently 65 mg/dL is trivial; predicting 60 minutes in advance that an apparently stable 110 mg/dL reading will decline dangerously requires understanding non-linear velocity and personal metabolic variance.
By eliminating retrospective leakage, our validation yields honest, reliable performance metrics that withstand external clinical scrutiny rather than collapsing upon real-world deployment.
Unlike cloud-heavy AI architectures that introduce latency and fail when cellular data drops, Madhu-AI is intentionally compressed to execute in milliseconds on smartphones directly paired to CGM sensors.
Bridging advanced computational research with medical technology providers, clinical researchers, and diabetic health platforms.
Collaborative algorithmic licensing or joint development with continuous glucose monitor manufacturers seeking enhanced early-warning software capabilities.
Incorporating predictive glucose intelligence into comprehensive chronic condition management apps and remote patient monitoring services.
Partnering with academic medical centers and endocrinology clinics to conduct prospective validation studies across specialized patient populations.
A definitive, sequential 4-phase execution trajectory taking Madhu-AI from proven mathematical models to a life-saving smartphone companion running in direct tandem with CGM hardware.
Established strict causal past-only preprocessing, multi-interval adapter layers (5-min and 15-min CGM telemetry), and validated the core predictive meta-model across four external clinical validation cohorts achieving 0.932–0.988 AUROC and 72–82 minute mean lead times.
Compressing model weights into an ultra-lightweight mobile inference engine designed to execute natively on iOS and Android devices. Engineering direct Bluetooth synchronization with CGM transmitter data streams to ensure sub-second local forecasting without cloud latency or cell coverage dependency.
Deploying the on-device companion in prospective observational clinical studies with clinical research partners. Evaluating real-world predictive lead time, true user alert compliance, reduction in nocturnal neuroglycopenic episodes, and patient cognitive peace of mind in daily living.
Licensing the validated predictive companion to CGM ecosystem providers and automated insulin delivery (AID) pump manufacturers, establishing an autonomous early-suspension loop that prevents hypoglycaemia before it manifests.
Current validation is based on multi-cohort retrospective clinical telemetry. Retrospective datasets may exhibit varying documentation of meal timestamps, unannounced exercise, and acute intercurrent illness. Live prospective studies are required to confirm that the observed lead-time and false-alert rates translate seamlessly into day-to-day patient behavior and clinical outcomes.
Key questions regarding lead times, low false-alarm thresholds, on-device telemetry, and clinical integration.
Madhu-AI leverages multi-scale temporal convolutions combined with leakage-free causal calibration. By pre-training across diverse longitudinal cohorts and optimizing for asymmetric loss penalties that prioritize true event discovery while constraining false alerts, the model maintains high sensitivity (90.1%–97.6%) while keeping false alert frequency under 1.86 alerts per day.
Yes. The distilled inference engine requires under 4.2 MB of storage and negligible compute power, executing forward passes in under 12 milliseconds on modern mobile chipsets. It ingests Bluetooth Low Energy telemetry directly from standard continuous glucose monitors offline.
Current commercial monitors rely on simple linear rate-of-fall extrapolations over 15 to 20 minutes, which routinely trigger false panic alarms during steep drop-offs that naturally plateau, or alert too late once neuroglycopenia has already impaired self-treatment. Madhu-AI models complex non-linear dynamics, giving users over an hour of actionable warning buffer.
Yes. Phase 4 of our roadmap focuses on direct API integration with automated insulin delivery (AID) closed-loop systems, enabling proactive pump suspension 60 minutes in advance, overcoming the delayed pharmacokinetics of subcutaneous insulin depots.
We welcome dialogue with endocrinologists, diabetes technology companies, clinical investigators, and machine learning researchers interested in evaluating predictive hypoglycaemia forecasting.
